JAK2 V617F es uno de los tres factores que definen la trombocitemia esencial (~50-60%; CALR ~...
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | BMA-JAK2-V617F-ET |
|---|---|
| Tipo | Relevancia terapéutica |
| Situación | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Enfermedades | DIS-ET |
| Fuentes | SRC-CIVIC SRC-ESMO-MPN-2015 SRC-NCCN-MPN-2025 SRC-PT1-HARRISON-2005 |
Hechos relativos a la posibilidad de adoptar medidas
| Biomarcador | BIO-JAK2 |
|---|---|
| Variante | V617F (exón 14 — presente en ~50-60% de la trombocitemia esencial) |
| Enfermedad | DIS-ET |
| El nivel de ESCAT | IA |
| Combinaciones recomendadas | low-dose aspirin (low-risk per SRC-NCCN-MPN-2025), hydroxyurea + aspirin (high-risk 1L per SRC-PT1-HARRISON-2005), interferon-alpha (preferred for younger high-risk per SRC-NCCN-MPN-2025, SRC-ESMO-MPN-2015), anagrelide (HU-resistant/intolerant 2L) |
| Resumen de las pruebas | JAK2 V617F is one of three defining drivers in essential thrombocythemia (~50-60%; CALR ~25-30%, MPL ~3-5%, triple-negative ~10-15%) and a WHO 2022 / ICC 2022 major diagnostic criterion (per SRC-NCCN-MPN-2025, SRC-ESMO-MPN-2015). Treatment is risk-stratified by IPSET-thrombosis (age, prior thrombosis, JAK2 V617F positivity, cardiovascular risk factors); high-risk → cytoreduction with hydroxyurea (PT1 trial Harrison 2005 — superior thrombosis-free survival vs anagrelide in HU-naive ET); low-risk → low-dose aspirin alone (or observation in CALR-mutated very-low-risk per SRC-ESMO-MPN-2015). |
Notas
ESCAT IA / OncoKB Level 1 — JAK2 mutation status is required for diagnosis and risk stratification (IPSET-thrombosis upgrades JAK2- positive patients into higher-risk strata per SRC-ESMO-MPN-2015). V617F allele burden does not determine treatment choice. Source-gap: SRC-NCCN-MPN-2025 STUB; awaits full ingestion.
Utilizado por
No se encuentran referencias inversas en el corpus YAML.